Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

Current Epidemiological Data on Asthma Management in South Korea from Qualitative Assessment of Asthma Management by Health Insurance Review and Assessment Service (HIRA)

  • Kim, So Ri (Division of Respiratory Medicine and Allergy, Department of Internal Medicine, Chonbuk National University Medical School) ;
  • Lee, Yong Chul (Division of Respiratory Medicine and Allergy, Department of Internal Medicine, Chonbuk National University Medical School) ;
  • Sung, Myung Ju (Health Insurance Review & Assessment Service) ;
  • Bae, Hye Won (Health Insurance Review & Assessment Service)
  • Received : 2017.05.30
  • Accepted : 2017.06.08
  • Published : 2017.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Since 2015, the Health Insurance Review and Assessment Service (HIRA) has performed annual qualitative assessments of asthma management provided by all medical institutions that care for asthma patients in Korea. According to the third report of qualitative assessment of asthma management in 2017, the assessment appears to have contributed to improving the quality of asthma care provided by medical institutions, especially primary clinics. However, there is still a gap between the ideal goals of asthma management and actual health care policies/regulations in real clinical settings, which leads to the state of standstill with respect to the quality of asthma management despite considerable efforts such as the qualitative assessment of asthma management by national agencies such as the HIRA. At this point, a harmonized approach is needed to raise the level of asthma management among several components including medical policies, efforts of academic associations such as education and distribution of the guideline for management, and reliable financial support by the government.

Keywords

References

  1. Health Insurance Review and Assessment Service [Internet]. Wonju: Health Insurance Review and Assessment Service; 2017 [cited 2017 May 16]. Available from: http://www.hira.or.kr.
  2. Global Initiative for Asthma. Global strategy for asthma management and prevention (updated 2017) [Internet]. Bethesda: Global Initiative for Asthma; 2017 [cited 2017 May 16]. Available from: http://www.ginasthma.org.
  3. Adams RJ, Fuhlbrigge A, Guilbert T, Lozano P, Martinez F. Inadequate use of asthma medication in the United States: results of the asthma in America national population survey. J Allergy Clin Immunol 2002;110:58-64. https://doi.org/10.1067/mai.2002.125489
  4. Cazzoletti L, Marcon A, Janson C, Corsico A, Jarvis D, Pin I, et al. Asthma control in Europe: a real-world evaluation based on an international population-based study. J Allergy Clin Immunol 2007;120:1360-7. https://doi.org/10.1016/j.jaci.2007.09.019
  5. Haahtela T, Laitinen LA. Asthma programme in Finland 1994-2004. Report of a Working Group. Clin Exp Allergy 1996;26 Suppl 1:1-24.
  6. Haahtela T, Tuomisto LE, Pietinalho A, Klaukka T, Erhola M, Kaila M, et al. A 10 year asthma programme in Finland: major change for the better. Thorax 2006;61:663-70. https://doi.org/10.1136/thx.2005.055699
  7. Peura S, Martikainen J, Klaukka T. Use and costs of asthma medication in 1980s. Publication M: 72. Helsinki: Social Insurance Institution; 1990.
  8. Klaukka T, Hirvonen A, Karhula K, Peura S. Good and bad news from asthma. Asthma barometer 2004. Suom Laakaril 2004;42:4002-4.

Cited by

  1. Potential of serum soluble CD93 as a biomarker for asthma in an ovalbumin-induced asthma murine model vol.23, pp.5, 2018, https://doi.org/10.1080/1354750x.2018.1443510
  2. Soluble CD93 in allergic asthma vol.10, pp.None, 2020, https://doi.org/10.1038/s41598-019-57176-2
  3. Challenges faced in managing adult asthma: A perspective from Asian countries vol.25, pp.12, 2017, https://doi.org/10.1111/resp.13935
  4. Short-Acting Beta2-Agonist Use in Asthma in Korea: A 10-Year Population-Based Study vol.13, pp.6, 2017, https://doi.org/10.4168/aair.2021.13.6.945
  5. The nationwide retrospective cohort study by Health Insurance Review and Assessment Service proves that asthma management decreases the exacerbation risk of asthma vol.11, pp.1, 2017, https://doi.org/10.1038/s41598-021-81022-z
  6. Does the Use of Asthma-Controller Medication in Accordance with Guidelines Reduce the Incidence of Acute Exacerbations and Healthcare Costs? vol.85, pp.1, 2017, https://doi.org/10.4046/trd.2021.0087